Title :

Growth, stool consistency and bone mineral content in healthy term infants fed sn-2-palmitate-enriched starter infant formula: A randomized, double-blind, multicentre clinical trial.

Author(s) :

Beghin, Laurent [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Marchandise, Xavier [Auteur]
Lien, Eric [Auteur]
Bricout, Myriam [Auteur]
Bernet, Jean-Paul [Auteur]
Lienhardt, Jean-Francois [Auteur]
Jeannerot, Francoise [Auteur]
Menet, Vincent [Auteur]
Requillart, Jean-Christophe [Auteur]
Marx, Jacques [Auteur]
De Groot, Nanda [Auteur]
Jaeger, Jonathan [Auteur]
Steenhout, Philippe [Auteur]
Turck, Dominique [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]

Journal title :

Clinical nutrition (Edinburgh, Scotland)

Abbreviated title :

Clin. Nutr.

Publication date :

2018-06-01

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

BACKGROUND: Palmitate in breast milk is predominantly located in the triacylglycerol sn-2 position, while infant formulae contain palmitate predominantly in the sn-1 and sn-3 positions. During digestion, palmitate in ...
Show more >BACKGROUND: Palmitate in breast milk is predominantly located in the triacylglycerol sn-2 position, while infant formulae contain palmitate predominantly in the sn-1 and sn-3 positions. During digestion, palmitate in the sn-1 and sn-3 positions is hydrolyzed to free palmitic acid that can subsequently complex with calcium to form insoluble soaps; this may partially explain why formula-fed infants have harder stools than breast-fed infants. METHODS: This large (n = 488) randomized, double-blind, multicentre trial investigated whether increasing the sn-2 palmitate content of infant formula improves stool consistency and bone mineral content (measured by dual-energy x-ray absorptiometry), without affecting growth or health. From approximately 1 week to 4 months of age, infants were exclusively fed one of three formulae: i) control formula (CF; 16% of total palmitate at sn-2; n = 162), (ii) experimental formula 1 (EF1; 43% of total palmitate at sn-2; n = 166) or (iii) experimental formula 2 (EF2; 51% of total palmitate at sn-2; n = 160). RESULTS: Intention-to-treat analysis showed softer stools in both EF groups (vs. CF) at ages 2 weeks and 1 and 2 months (p </= 0.01), but not 3 and 4 months. At 4 months, all groups had similar growth outcomes while bone mineral content was significantly higher in EF1 (p = 0.0012) and EF2 (p = 0.0002) compared with CF. Comparison of reported adverse events up to 12 months revealed no differences among groups. All 3 infant formulae exhibited equally good digestive tolerance. CONCLUSIONS: Formulae enriched in sn-2 palmitate fed in early infancy are safe, improve stool consistency (from 2 weeks to 2 months) and increase bone mineral content (at 4 months).Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Research team(s) :

Nutritional modulation of inflammation and infection

Submission date :

2019-03-01T14:08:06Z
2019-06-06T10:04:19Z